1/13
08:00 am
ntra
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
Low
Report
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling
1/12
10:00 am
ntra
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
Low
Report
Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA
1/12
07:17 am
ntra
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
Low
Report
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc..
1/11
10:48 pm
ntra
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
Medium
Report
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
1/11
09:22 am
ntra
Breakeven On The Horizon For Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]
Medium
Report
Breakeven On The Horizon For Natera, Inc. (NASDAQ:NTRA) [Yahoo! Finance]
1/10
05:43 am
ntra
Natera (NASDAQ:NTRA) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Medium
Report
Natera (NASDAQ:NTRA) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
1/8
04:01 pm
ntra
Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial
Low
Report
Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial
1/7
10:58 am
ntra
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/7
06:05 am
ntra
Natera (NASDAQ:NTRA) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
1/5
07:25 pm
ntra
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
Medium
Report
Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI
1/5
10:16 am
ntra
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Natera (NASDAQ:NTRA) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/5
07:00 am
ntra
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
Medium
Report
Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology
1/3
05:42 am
ntra
Natera (NASDAQ:NTRA) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
Natera (NASDAQ:NTRA) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
12/31
12:08 pm
ntra
Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study [Yahoo! Finance]
Low
Report
Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study [Yahoo! Finance]
12/22
08:02 am
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $250.00 to $285.00. They now have a "buy" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $250.00 to $285.00. They now have a "buy" rating on the stock.
12/22
08:00 am
ntra
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/18
08:00 am
ntra
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
Low
Report
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
12/16
08:00 am
ntra
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
Low
Report
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
12/15
02:24 pm
ntra
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an "overweight" rating on the stock.
Low
Report
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an "overweight" rating on the stock.
12/15
08:04 am
ntra
Natera (NASDAQ:NTRA) was given a new $205.00 price target on by analysts at Wells Fargo & Company.
Low
Report
Natera (NASDAQ:NTRA) was given a new $205.00 price target on by analysts at Wells Fargo & Company.
12/15
07:02 am
ntra
Natera (NASDAQ:NTRA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Low
Report
Natera (NASDAQ:NTRA) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
12/12
08:00 am
ntra
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
Low
Report
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
12/10
08:52 pm
ntra
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer [Yahoo! Finance]
Low
Report
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer [Yahoo! Finance]
12/10
07:57 pm
ntra
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer
Low
Report
Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer
12/9
08:00 am
ntra
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting
Low
Report
Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting